H. DİNÇASLAN Et Al. , "The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency," 50. CONGRESS OF SIOP , 2018
DİNÇASLAN, H. Et Al. 2018. The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency. 50. CONGRESS OF SIOP .
DİNÇASLAN, H., ÜNAL, E., TAÇYILDIZ, N., Tanyildiz, H. G., KULOĞLU, Z., KAYGUSUZ, G., ... ÇAKMAK, A. M.(2018). The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency . 50. CONGRESS OF SIOP
DİNÇASLAN, HANDAN Et Al. "The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency," 50. CONGRESS OF SIOP, 2018
DİNÇASLAN, HANDAN U. Et Al. "The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency." 50. CONGRESS OF SIOP , 2018
DİNÇASLAN, H. Et Al. (2018) . "The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency." 50. CONGRESS OF SIOP .
@conferencepaper{conferencepaper, author={HANDAN UĞUR DİNÇASLAN Et Al. }, title={The First Report Related toFirst-Line Therapy with Anti-CD30 CombinedModified Chemotherapy in a Child withHodgkin Disease Underlying CombinedImmunodeficiency}, congress name={50. CONGRESS OF SIOP}, city={}, country={}, year={2018}}